CN104997738A - Medicine lansoprazole compound dry suspension treating gastropathy - Google Patents
Medicine lansoprazole compound dry suspension treating gastropathy Download PDFInfo
- Publication number
- CN104997738A CN104997738A CN201510483700.5A CN201510483700A CN104997738A CN 104997738 A CN104997738 A CN 104997738A CN 201510483700 A CN201510483700 A CN 201510483700A CN 104997738 A CN104997738 A CN 104997738A
- Authority
- CN
- China
- Prior art keywords
- lansoprazole
- weight portion
- dry suspension
- weight
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Abstract
The invention relates to a medicine lansoprazole compound dry suspension treating gastropathy, and belongs to the technical field of medicine. The compound dry suspension is prepared from lansoprazole, lactose, mannitol, disodium hydrogen phosphate, xanthan gum, sucralose and silicon dioxide. The lansoprazole is a new crystal type compound. An X-ray powder diffraction diagram obtained through Cu-Kalpha ray measurement is shown as the figure 1. The lansoprazole is different from lansoprazole reported in the prior art. As is found through a test, the lansoprazole crystal compound does not contain an impurity E, the content of an impurity A and the content of an impurity B are obviously reduced, and besides the content changes little along with prolonging of storage time. The dry suspension has good flowability and remarkably improves the dissolution rate, and the lansoprazole dry suspension prepared from the crystal type compound is good in stability and low in impurity content.
Description
Technical field
The invention belongs to medical art, relate to a kind of medicine Lansoprazole composition dry suspension for the treatment of gastropathy.
Background technology
The benzimidazoles derivative with antiacid effect that lansoprazole is developed in December, 1991 by Japanese Wu Tian company, it acts on the H+-K+-ATP enzyme of parietal cell, the H+ of parietal cell can not be transported in stomach go, so that gastric acid amount greatly reduces in gastric juice, be used for the treatment of gastric ulcer, duodenal ulcer and reflux esophagitis, and be used for eliminating pylorus.
Lansoprazole is novel proton pump inhibitor, it is the upgraded product of omeprazole, lansoprazole is because importing fluorine at pyridine ring 4 side chains and have trifluoro ethoxy substituent group, make the comparatively omeprazole raising more than 30% of its bioavailability, lipotropy is also better than omeprazole, therefore this product promptly can play drug effect through parietal cell film changes sulfenic acids and time sulfonyl derivative in acid condition, the bacteriostatic activity of HP is risen to four times of omeprazole.
A lot of crystal formations of lansoprazole are disclosed, as the 1.5 crystal types (II type) of the anhydrous crystal forms (I type) and lansoprazole that disclose lansoprazole in CN1355798A in prior art.Describe lansoprazole A crystal formation and B crystal form in US2009/0018339A1, in fact, B crystal form is unstable, is metastable-state crystal, can experience solid-to-solid transition under certain condition, forms A crystal formation.
CN102558154A discloses a kind of lansoprazole crystalline compounds, and the X ray powder diffraction represented with the 2 θ ± 0.2 ° angle of diffraction demonstrates characteristic diffraction peak at 5.8 °, 7.5 °, 9.1 °, 11.8 °, 12.1 °, 12.8 °, 13.3 °, 15.6 °, 16.7 °, 18.3 °, 20.4 °, 25.7 °, 26.8 ° and 31.5 ° of places.
CN102180866A discloses M crystal formation and the N crystal form of lansoprazole, and wherein the X ray powder diffraction of M crystal formation at angle of diffraction 2 θ is: 6.519,9.373,9.989,10.548,13.123,14.298,14.914,15.642,18.104,18.720,19.672,20.231,24.205,25.492,27.899 time there is characteristic peak; The X-ray powder diffraction of N crystal form at angle of diffraction 2 θ is: 5.438,7.062,8.230,9.216,11.022,11.789,12.610,13.541,20.603,21.862,26.242 time there is characteristic peak.
CN1681802A discloses three kinds of crystalline solid form of lansoprazole, and called after D, E and F type, also discloses the preparation method of these crystalline solid form of lansoprazole simultaneously respectively.
CN103664889A also discloses a kind of Lansoprazole crystal compound.
Lansoprazole has a chiral centre sulphur atom, therefore has two optical isomers.Research shows that the lansoprazole drug effect of (R)-configuration is obviously better than lansoprazole raceme, and optically active lansoprazole toxic and side effects is lower than raceme.
But according to the chemical constitution feature of lansoprazole, lansoprazole is being produced, is being deposited easy generation following impurity A, impurity B and impurity E in process, and these trace impurities can affect drug quality.Although some crystal formation of above-mentioned lansoprazole improves its hygroscopicity, dissolubility or stability to a certain extent, the present inventor's its result after the impurity of some crystal formation above-mentioned being carried out to investigation is unsatisfactory.
The present inventor starts with from the research of lansoprazole solid chemical substance existence, has prepared a kind of new compound of Lansoprazole crystal through a large amount of tests.
The lansoprazole of prior art, owing to having stronger hygroscopicity, causes its mobility bad, is unfavorable for the operation of production process; And due to almost insoluble in water, belong to low solubility, Thief zone class medicine, dissolution rate is the rate-limiting step that it absorbs.Directly affect the speed of onset, the power of drug effect due to dissolution rate and hold time, therefore, the dissolution rate improving insoluble drug usually becomes the first step improving its oral administration biaavailability.The present invention finds by test the dissolution that Lansoprazole crystal compound provided by the present invention has good mobility and significantly improves further.
Some crystal formation of the lansoprazole that the preparation method that prior art provides obtains improves from stability, hygroscopicity or dissolubility aspect mostly.But according to the chemical constitution feature of lansoprazole, lansoprazole in production, deposit in process and easily produce impurity A, impurity B and impurity E, these trace impurities can affect the quality of medicine, and the impurity A of the lansoprazole that the method for prior art obtains, impurity B and impurity E are not effectively controlled.
The present inventor is after having carried out large quantifier elimination to it, obtain above-mentioned preparation method, and surprisingly find the Lansoprazole crystal compound E free from foreign meter that the above-mentioned preparation method of employing is obtained, and the content of impurity A and impurity B significantly reduces, and along with its changes of contents of prolongation of period of storage less.
The dissolution that Lansoprazole crystal compound provided by the present invention has good mobility and significantly improves is found further by test.
Compared with prior art, tool of the present invention has the following advantages:
Lansoprazole crystal compound provided by the invention E free from foreign meter, and the content of impurity A and impurity B significantly reduces, and along with its changes of contents of prolongation of period of storage is less, the dissolution that there is excellent mobility and significantly improve, the lansoprazole dry suspension good stability utilizing this crystal-form compound to make, impurity content is low.
Summary of the invention
Goal of the invention of the present invention is to provide a kind of medicine Lansoprazole composition dry suspension for the treatment of gastropathy.
In order to complete object of the present invention, the technical scheme of employing is:
The present invention relates to a kind of medicine Lansoprazole composition dry suspension for the treatment of gastropathy, described compositions dry suspension is made up of lansoprazole, lactose, mannitol, sodium hydrogen phosphate, xanthan gum, sucralose, silicon dioxide; Described lansoprazole is crystal, and the X-ray powder diffraction pattern that the measurement of use Cu-K alpha ray obtains as shown in Figure 1.
First optimal technical scheme of the present invention is: with parts by weight, and described compositions dry suspension is made up of the lansoprazole of 0.1-0.2 weight portion, the lactose of 1.5-1.7 weight portion, the mannitol of 1.3-1.5 weight portion, the sodium hydrogen phosphate of 0.5-0.7 weight portion, the xanthan gum of 0.1-0.2 weight portion, the sucralose of 0.02-0.04 weight portion, the silicon dioxide of 0.05-0.07 weight portion.
Second optimal technical scheme of the present invention is: with parts by weight, and described compositions dry suspension is made up of the lansoprazole of 0.15 weight portion, the lactose of 1.6 weight portions, the mannitol of 1.4 weight portions, the sodium hydrogen phosphate of 0.6 weight portion, the xanthan gum of 0.15 weight portion, the sucralose of 0.03 weight portion, the silicon dioxide of 0.06 weight portion.
3rd optimal technical scheme of the present invention is: the preparation method of described compositions dry suspension comprises the following steps:
1) supplementary material process: raw material lansoprazole is crossed 80 mesh sieves with oscillating sieving machine;
2) weigh: weigh each supplementary material according to technology preparation amount;
3) always mix: the supplementary material of whole recipe quantity is joined in three-dimensional mixer, mixing velocity 12r/min, open mixer and mix 45 minutes;
4) subpackage: granule is joined subpackage in particles packing machine, controls content uniformity and meets inner quality standard.
According to the chemical constitution feature of lansoprazole, lansoprazole in production, deposit in process and easily produce impurity A, impurity B and impurity E, these trace impurities can affect the quality of medicine.Prior art provide some crystal formation of lansoprazole mostly improve from stability, hygroscopicity or dissolubility aspect, its impurity is not effectively controlled.
The present inventor is after having carried out large quantifier elimination to it, obtain a kind of lansoprazole crystal compound, and surprisingly find described compound of Lansoprazole E free from foreign meter, and the content of impurity A and impurity B significantly reduces, and along with its changes of contents of prolongation of period of storage less.
The dissolution that compound of Lansoprazole provided by the present invention has good mobility and significantly improves is found further by test.
The preparation method of the lansoprazole crystal in the present composition comprises the following steps:
(1) ground by lansoprazole crude product, cross 60 mesh sieves, then joining volume is in the methanol of 7 times of lansoprazole weight, and 130 revs/min are stirred 10 minutes;
Add the acetone that volume is 5 times of lansoprazole weight under (2) 110 revs/min of stirrings, be warming up to 30 DEG C simultaneously;
(3) after solution adds, leave standstill 3 hours, the volume dripping 0 DEG C under 150 revs/min of conditions stirred is 8 times of ether of lansoprazole weight, the mixed solution of chloroform, and the volume ratio of ether, chloroform is at the uniform velocity dropwise in 2:3,2h;
(4) be cooled to-10 DEG C after being added dropwise to complete, continue to stir 3h under the stir speed (S.S.) of 95 revs/min, leave standstill 1h crystallize out, filter, washing, vacuum drying obtains lansoprazole crystal.
Accompanying drawing explanation
Fig. 1 is the X-ray powder diffraction that the lansoprazole crystal of the embodiment of the present invention 1 preparation uses the measurement of Cu-K alpha ray to obtain.
Detailed description of the invention
Below by specific embodiment, summary of the invention of the present invention is described in further detail, but does not therefore limit content of the present invention.
embodiment 1:the preparation of lansoprazole crystal
(1) ground by lansoprazole crude product, cross 60 mesh sieves, then joining volume is in the methanol of 7 times of lansoprazole weight, and 130 revs/min are stirred 10 minutes;
Add the acetone that volume is 5 times of lansoprazole weight under (2) 110 revs/min of stirrings, be warming up to 30 DEG C simultaneously;
(3) after solution adds, leave standstill 3 hours, the volume dripping 0 DEG C under 150 revs/min of conditions stirred is 8 times of ether of lansoprazole weight, the mixed solution of chloroform, and the volume ratio of ether, chloroform is at the uniform velocity dropwise in 2:3,2h;
(4) be cooled to-10 DEG C after being added dropwise to complete, continue to stir 3h under the stir speed (S.S.) of 95 revs/min, leave standstill 1h crystallize out, filter, washing, vacuum drying obtains lansoprazole crystal.
The X-ray powder diffraction pattern that the lansoprazole crystal prepared uses the measurement of Cu-K alpha ray to obtain as shown in Figure 1.
embodiment 2:the preparation of lansoprazole dry suspension
Prescription: with parts by weight, the Lansoprazole crystal compound 0.15 part that embodiment 1 is obtained, lactose 1.5 parts, 1.3 parts, mannitol, sodium hydrogen phosphate 0.5 part, xanthan gum 0.1 part, sucralose 0.02 part, silicon dioxide 0.05 part.
Preparation method:
1) supplementary material process: raw material lansoprazole is crossed 80 mesh sieves with oscillating sieving machine;
2) weigh: weigh each supplementary material according to technology preparation amount;
3) always mix: the supplementary material of whole recipe quantity is joined in three-dimensional mixer, mixing velocity 12r/min, open mixer and mix 45 minutes;
4) subpackage: granule is joined subpackage in particles packing machine, controls content uniformity and meets inner quality standard.
embodiment 3:the preparation of lansoprazole dry suspension
Prescription: with parts by weight, the Lansoprazole crystal compound 0.15 part that embodiment 1 is obtained, lactose 1.6 parts, 1.4 parts, mannitol, sodium hydrogen phosphate 0.6 part, xanthan gum 0.15 part, sucralose 0.03 part, silicon dioxide 0.06 part.
Preparation method:
1) supplementary material process: raw material lansoprazole is crossed 80 mesh sieves with oscillating sieving machine;
2) weigh: weigh each supplementary material according to technology preparation amount;
3) always mix: the supplementary material of whole recipe quantity is joined in three-dimensional mixer, mixing velocity 12r/min, open mixer and mix 45 minutes;
4) subpackage: granule is joined subpackage in particles packing machine, controls content uniformity and meets inner quality standard.
embodiment 4:the preparation of lansoprazole dry suspension
Prescription: with parts by weight, the Lansoprazole crystal compound 0.15 part that embodiment 1 is obtained, lactose 1.7 parts, 1.5 parts, mannitol, sodium hydrogen phosphate 0.7 part, xanthan gum 0.2 part, sucralose 0.04 part, silicon dioxide 0.07 part.
Preparation method:
1) supplementary material process: raw material lansoprazole is crossed 80 mesh sieves with oscillating sieving machine;
2) weigh: weigh each supplementary material according to technology preparation amount;
3) always mix: the supplementary material of whole recipe quantity is joined in three-dimensional mixer, mixing velocity 12r/min, open mixer and mix 45 minutes;
4) subpackage: granule is joined subpackage in particles packing machine, controls content uniformity and meets inner quality standard.
test example 1:determination of foreign matter in stability test
Prepare 3 batch samples according to embodiment 1, be numbered 001,002,003
Reference substance 1: according to " improvement in synthesis of lansoprazole " [Liu Yanfei, Li Yongxin etc. the improvement in synthesis [J] of lansoprazole, fine-chemical intermediate, 2011, the lansoprazole fine work of method synthesis 41(3): 26-28 and 42], m.p.169-171 DEG C (decomposition).
Reference substance 2: according to the lansoprazole form D that the method for CN1681802A embodiment 2 is obtained;
Reference substance 3: commercially available lansoprazole bulk drug
Determination of foreign matter method: with reference to " in lansoprazole intestine dissolving capsule the structural identification of impurity, inspection and control " [Xia Guimin, Deng. the structural identification of impurity, inspection and control in lansoprazole intestine dissolving capsule. pharmaceutical analysis impurity, 2012,32(6): 1022-1027] in method measure each impurity content in each sample.The results are shown in Table shown in 1:
Determination of foreign matter in table 1, lansoprazole stability test
As can be seen from the above results, Lansoprazole crystal compound provided by the invention E free from foreign meter, and the content of impurity A and impurity B comparatively reference substance significantly reduce.
test example 2: fluidity test
Method: prepare 3 batch samples according to embodiment 1, be numbered 001,002,003, sample respectively, adopt fixed funnel method, funnel is placed in the suitable height on graph paper, lansoprazole is freely flowed down from bell mouth, until the cone top formed contacts with bell mouth, measures hypotenuse and the horizontal angle (θ angle of repose) of lansoprazole accumulation horizon.The results are shown in Table shown in 2:
The fluidity test result of table 2, lansoprazole
As can be seen from the above results, Lansoprazole crystal compound provided by the invention has good mobility.
test example 3: Dissolution Rate Testing
Prepare 3 batch samples according to embodiment 1, be numbered 001,002,003
Reference substance 1: according to " improvement in synthesis of lansoprazole " [Liu Yanfei, Li Yongxin etc. the improvement in synthesis [J] of lansoprazole, fine-chemical intermediate, 2011, the lansoprazole fine work of method synthesis 41(3): 26-28 and 42], m.p.169-171 DEG C (decomposition).
Reference substance 2: according to the lansoprazole form D that the method for CN1681802A embodiment 2 is obtained;
Reference substance 3: commercially available lansoprazole bulk drug
Method: different lansoprazoles is investigated dissolution according to Pharmacopoeia of the People's Republic of China version in 2010 two annex X C method second methods.With pH6.8 phosphate buffer 900mL for dissolution medium, temperature is 37 DEG C, and rotating speed is 75rmin
-1, the medication amount in each testing sample is 30mg.Adopt ultraviolet spectrophotometry to carry out dissolution determination respectively at 5,10,15,20 and 30min sampling, determined wavelength is 284nm, at 5-25mgL
-1internal linear relation is good, and the response rate, Precision Experiment all meet methodology requirement.The results are shown in Table 3:
The dissolution of table 3, lansoprazole investigates result
As can be seen from the above results, the dissolution of Lansoprazole crystal compound provided by the invention has improve extremely significantly compared to contrast medicine.
Claims (5)
1. treat a medicine Lansoprazole composition dry suspension for gastropathy, it is characterized in that: described compositions dry suspension is made up of lansoprazole, lactose, mannitol, sodium hydrogen phosphate, xanthan gum, sucralose, silicon dioxide; Described lansoprazole is crystal, and the X-ray powder diffraction pattern that the measurement of use Cu-K alpha ray obtains as shown in Figure 1.
2. the medicine Lansoprazole composition dry suspension for the treatment of gastropathy according to claim 1, it is characterized in that: with parts by weight, described compositions is made up of the lansoprazole of 0.1-0.2 weight portion, the lactose of 1.5-1.7 weight portion, the mannitol of 1.3-1.5 weight portion, the sodium hydrogen phosphate of 0.5-0.7 weight portion, the xanthan gum of 0.1-0.2 weight portion, the sucralose of 0.02-0.04 weight portion, the silicon dioxide of 0.05-0.07 weight portion.
3. the medicine Lansoprazole composition dry suspension for the treatment of gastropathy according to claim 2, it is characterized in that: with parts by weight, described compositions is made up of the lansoprazole of 0.15 weight portion, the lactose of 1.6 weight portions, the mannitol of 1.4 weight portions, the sodium hydrogen phosphate of 0.6 weight portion, the xanthan gum of 0.15 weight portion, the sucralose of 0.03 weight portion, the silicon dioxide of 0.06 weight portion.
4., according to the medicine Lansoprazole composition dry suspension of the arbitrary described treatment gastropathy of claim 1-3, it is characterized in that, the preparation method of described compositions dry suspension comprises the following steps:
1) supplementary material process: raw material lansoprazole is crossed 80 mesh sieves with oscillating sieving machine;
2) weigh: weigh each supplementary material according to technology preparation amount;
3) always mix: the supplementary material of whole recipe quantity is joined in three-dimensional mixer, mixing velocity 12r/min, open mixer and mix 45 minutes;
4) subpackage: granule is joined subpackage in particles packing machine, controls content uniformity and meets inner quality standard.
5. the medicine Lansoprazole composition dry suspension for the treatment of gastropathy according to claim 1, it is characterized in that, the preparation method of the crystal of described lansoprazole comprises the following steps:
(1) ground by lansoprazole crude product, cross 60 mesh sieves, then joining volume is in the methanol of 7 times of lansoprazole weight, and 130 revs/min are stirred 10 minutes;
Add the acetone that volume is 5 times of lansoprazole weight under (2) 110 revs/min of stirrings, be warming up to 30 DEG C simultaneously;
(3) after solution adds, leave standstill 3 hours, the volume dripping 0 DEG C under 150 revs/min of conditions stirred is 8 times of ether of lansoprazole weight, the mixed solution of chloroform, and the volume ratio of ether, chloroform is at the uniform velocity dropwise in 2:3,2h;
(4) be cooled to-10 DEG C after being added dropwise to complete, continue to stir 3h under the stir speed (S.S.) of 95 revs/min, leave standstill 1h crystallize out, filter, washing, vacuum drying obtains lansoprazole crystal.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510483700.5A CN104997738A (en) | 2015-08-10 | 2015-08-10 | Medicine lansoprazole compound dry suspension treating gastropathy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510483700.5A CN104997738A (en) | 2015-08-10 | 2015-08-10 | Medicine lansoprazole compound dry suspension treating gastropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104997738A true CN104997738A (en) | 2015-10-28 |
Family
ID=54370787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510483700.5A Withdrawn CN104997738A (en) | 2015-08-10 | 2015-08-10 | Medicine lansoprazole compound dry suspension treating gastropathy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104997738A (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000078729A1 (en) * | 1999-06-18 | 2000-12-28 | Instytut Farmaceutyczny | Crystalline forms of lansoprazole |
| WO2000078745A2 (en) * | 1999-06-17 | 2000-12-28 | Takeda Chemical Industries, Ltd. | Crystalline form of (r)-2-[[[3-methyl- 4- (2,2,2,- trifluoroethoxy) -2- pyridinyl] methyl] sulfinyl] -1h-benzimidazole |
| EP1000943B1 (en) * | 1998-11-16 | 2004-02-18 | Eisai Co., Ltd. | Sulfoxide compounds and acetone complexes, and a process for producing the same |
| CN1681802A (en) * | 2002-03-27 | 2005-10-12 | 特瓦制药工业有限公司 | Lansoprazole polymorphs and processes for preparation thereof |
| CN101313895A (en) * | 2008-06-26 | 2008-12-03 | 江苏奥赛康药业有限公司 | Lansoprazole freeze-dried injection |
| CN102180866A (en) * | 2011-05-23 | 2011-09-14 | 中山大学 | New crystal form of lansoprazole and preparation method and application thereof |
| CN102399212A (en) * | 2010-08-23 | 2012-04-04 | 江苏豪森医药集团有限公司 | Dexlansoprazole crystal form and preparation method thereof |
| CN102558154A (en) * | 2012-02-24 | 2012-07-11 | 海南锦瑞制药股份有限公司 | Lansoprazole crystalline compound, enteric capsule thereof and preparation method of Lansoprazole crystalline compound |
| CN102875531A (en) * | 2011-07-15 | 2013-01-16 | 上海睿智化学研究有限公司 | (R)-lansoprazole unhydrous crystal and preparation method thereof |
| CN103012369A (en) * | 2011-05-23 | 2013-04-03 | 中山大学 | Lansoprazole N crystal form and preparation method and application thereof |
-
2015
- 2015-08-10 CN CN201510483700.5A patent/CN104997738A/en not_active Withdrawn
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1000943B1 (en) * | 1998-11-16 | 2004-02-18 | Eisai Co., Ltd. | Sulfoxide compounds and acetone complexes, and a process for producing the same |
| WO2000078745A2 (en) * | 1999-06-17 | 2000-12-28 | Takeda Chemical Industries, Ltd. | Crystalline form of (r)-2-[[[3-methyl- 4- (2,2,2,- trifluoroethoxy) -2- pyridinyl] methyl] sulfinyl] -1h-benzimidazole |
| WO2000078729A1 (en) * | 1999-06-18 | 2000-12-28 | Instytut Farmaceutyczny | Crystalline forms of lansoprazole |
| CN1681802A (en) * | 2002-03-27 | 2005-10-12 | 特瓦制药工业有限公司 | Lansoprazole polymorphs and processes for preparation thereof |
| CN101313895A (en) * | 2008-06-26 | 2008-12-03 | 江苏奥赛康药业有限公司 | Lansoprazole freeze-dried injection |
| CN102399212A (en) * | 2010-08-23 | 2012-04-04 | 江苏豪森医药集团有限公司 | Dexlansoprazole crystal form and preparation method thereof |
| CN102180866A (en) * | 2011-05-23 | 2011-09-14 | 中山大学 | New crystal form of lansoprazole and preparation method and application thereof |
| CN103012369A (en) * | 2011-05-23 | 2013-04-03 | 中山大学 | Lansoprazole N crystal form and preparation method and application thereof |
| CN102875531A (en) * | 2011-07-15 | 2013-01-16 | 上海睿智化学研究有限公司 | (R)-lansoprazole unhydrous crystal and preparation method thereof |
| CN102558154A (en) * | 2012-02-24 | 2012-07-11 | 海南锦瑞制药股份有限公司 | Lansoprazole crystalline compound, enteric capsule thereof and preparation method of Lansoprazole crystalline compound |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108349978A (en) | (S) solid form and preparation of -4- (8- amino -3- (1- (butyl- 2- alkynes acyl group) pyrrolidin-2-yl) imidazo [1,5-a] pyrazine -1- bases)-N- (pyridine -2- bases) benzamide | |
| CN101869551B (en) | Temozolomide freeze-dried preparation | |
| CN105753904B (en) | A kind of process for purification of Tedizolid Phosphate | |
| CN104873511A (en) | Medical lansoprazole composition for treating gastric ulcer | |
| JP4455815B2 (en) | Method for producing C-crystal of omeprazole | |
| CN104997738A (en) | Medicine lansoprazole compound dry suspension treating gastropathy | |
| CN104829594A (en) | Pharmaceutical lansoprazole compound for treating gastric ulcer | |
| CN104922080A (en) | Pharmaceutical ilaprazole sodium freeze-dried powder injection composition for treating digestive system diseases | |
| CN105106129A (en) | Pharmaceutical lansoprazole composite granules for treating digestive system diseases | |
| CN111217757B (en) | Enzalutamide compound and pharmaceutical composition preparation thereof | |
| CN105147681A (en) | Lansoprazole composition drug for resisting gastric acid secretion | |
| CN104958276A (en) | Pharmaceutical lansoprazole composition capsule for treating gastric ulcer | |
| CN105168153A (en) | Medicinal lansoprazole composition lyophilized powder injection for treating gastric ulcer | |
| CN105106206A (en) | Medicine of lansoprazole composition for treating digestive system diseases | |
| CN105125540A (en) | Lansoprazole drug composite for treating gastric ulcers | |
| CN112375093A (en) | Keliboro crystal form compound and preparation method thereof | |
| CN106432274A (en) | Crystalline compound of drug ceftriaxone sodium for treating surgical operation infections | |
| CN105106205A (en) | Medicine of lansoprazole composition for treating stomach diseases | |
| CN106397455B (en) | A kind of anti-infectives Ceftibuten crystalline compounds and combinations thereof | |
| CN104997739A (en) | Medicine lansoprazole composition freeze-dried powder injection for treating digestive system diseases | |
| CN104844576B (en) | A kind of Lansoprazole or Dexlansoprazole crystal-form compound and preparation method thereof | |
| CN104761463B (en) | D pantothenic acid sodium crystal and its production and use | |
| CN106397402B (en) | A kind of esomeprazole magnesium crystal-form compound and preparation method thereof | |
| JP5589097B2 (en) | Dasatinib polycrystal, preparation method thereof and drug composition | |
| CN106432275A (en) | Method for preparing crystalline ceftriaxone sodium compound as drug for treating surgical infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20151028 |